Home >> Research Area >>Metabolism>>SGLT>> Canagliflozin

Canagliflozin

SGLT2 inhibitor,potent and selective CAS# 842133-18-0

Canagliflozin

Catalog No. BCC3696----Order now to get a substantial discount!

Product Name & Size Price Stock
Canagliflozin: 5mg $17 In Stock
Canagliflozin: 10mg Please Inquire In Stock
Canagliflozin: 20mg Please Inquire Please Inquire
Canagliflozin: 50mg Please Inquire Please Inquire
Canagliflozin: 100mg Please Inquire Please Inquire
Canagliflozin: 200mg Please Inquire Please Inquire
Canagliflozin: 500mg Please Inquire Please Inquire
Canagliflozin: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Canagliflozin

Number of papers citing our products

Chemical structure

Canagliflozin

3D structure

Chemical Properties of Canagliflozin

Cas No. 842133-18-0 SDF Download SDF
PubChem ID 24812758 Appearance Powder
Formula C24H25FO5S M.Wt 444.52
Type of Compound N/A Storage Desiccate at -20°C
Synonyms JNJ 24831754ZAE; JNJ 28431754; JNJ 28431754AAA; TA 7284
Solubility DMSO : ≥ 50 mg/mL (112.48 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name (2S,3R,4R,5S,6R)-2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
SMILES CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F
Standard InChIKey XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
Standard InChI InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Canagliflozin

TargetshSGLT2rSGLT2mSGLT2   
IC504.4 nM3.7 nM2 nM   

Canagliflozin Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Canagliflozin Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Canagliflozin

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.2496 mL 11.2481 mL 22.4962 mL 44.9924 mL 56.2404 mL
5 mM 0.4499 mL 2.2496 mL 4.4992 mL 8.9985 mL 11.2481 mL
10 mM 0.225 mL 1.1248 mL 2.2496 mL 4.4992 mL 5.624 mL
50 mM 0.045 mL 0.225 mL 0.4499 mL 0.8998 mL 1.1248 mL
100 mM 0.0225 mL 0.1125 mL 0.225 mL 0.4499 mL 0.5624 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Canagliflozin

Canagliflozin is a novel, potent, and highly selective sodium glucose co-transporter (SGLT) 2 inhibitor [1]. It has been proved that Canagliflozin can increase urine glucose excretion by reducing the renal glucose threshold and by decreasing the filtered glucose re-absorption [2].

Canagliflozin has been shown to inhibit the Na+-mediated 14C-AMG intakes in CHO-hSGLT2, CHO-rat SGLT2 and CHO-mouse SGLT2 with IC50 values of 4.4, 3.7 and 2.0 nM, respectively [1].

Canagliflozin has been reported to reduce the blood glucose (BG) levels dose-dependently in both db/db Mice and Zucker diabetic fatty (ZDF) Rats. Additionally, canagliflozin has proved to decrease the respiratory exchange ratio, and body weight in DIO mice and ZDF rats [1].

Canagliflozin can be taken orally [1].

References:
[1] Liang Y1, Arakawa K, Ueta K, Matsushita Y, Kuriyama C Martin T, Du F, Liu Y, Xu J, Conway B, Conway J, Polidori D, Ways K, Demarest K. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One. 2012;7(2):e30555
[2] Sarnoski-Brocavich S, Hilas O. Canagliflozin (Invokana), a Novel Oral Agent For Type-2 Diabetes. P T. 2013 Nov;38(11):656-66

Featured Products
New Products
 

References on Canagliflozin

Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: a post hoc analysis of pooled data.[Pubmed:28327140]

Cardiovasc Diabetol. 2017 Mar 21;16(1):40.

BACKGROUND: Treatment of patients with type 2 diabetes mellitus (T2DM) and a history of cardiovascular (CV) disease or CV risk factors may present clinical challenges due to the presence of comorbid conditions and the use of concomitant medications. The sodium glucose co-transporter 2 inhibitor, Canagliflozin, has been shown to improve glycaemic control and reduce body weight and blood pressure (BP) with a favourable tolerability profile in a broad range of patients with T2DM. This post hoc analysis assessed the efficacy and safety of Canagliflozin in patients with T2DM based on CV disease history or CV risk factors. METHODS: Analyses were based on pooled data from four 26-week, placebo-controlled, Phase 3 studies that evaluated Canagliflozin 100 and 300 mg in patients with T2DM (N = 2313; mean HbA1c, 8.0%; body weight, 89 kg; systolic BP, 128 mmHg). Changes from baseline to week 26 in HbA1c, body weight, and systolic BP were assessed based on history of CV disease, history of hypertension, baseline statin use, and number of CV risk factors. Safety was assessed based on adverse event (AE) reports. RESULTS: At week 26, both Canagliflozin doses lowered HbA1c, body weight, and systolic BP compared with placebo in patients with and without CV disease history or risk factors. Placebo-subtracted HbA1c reductions with Canagliflozin 100 and 300 mg were similar in patients with a history of CV disease (-0.95 and -1.07%) versus no history of CV disease (-0.71 and -0.90%), history of hypertension (-0.72 and -0.89%) versus no history of hypertension (-0.73 and -0.95%), baseline statin use (-0.77 and -0.99%) versus no statin use (-0.69 and -0.85%), and 0-1 CV risk factor (-0.72 and -0.87%) versus >/=2 CV risk factors (-0.74 and -1.02%). Similar body weight and systolic BP reductions were seen with Canagliflozin versus placebo across subgroups. The incidence of AEs, AEs leading to discontinuation, and serious AEs was similar across subgroups. CONCLUSIONS: The efficacy and safety of Canagliflozin were generally consistent across subgroups of patients with T2DM and varying degrees of CV disease history or risk factors. Trial registration numbers and dates ClinicalTrials.gov: NCT01081834, 4 March 2010; NCT01106625, 1 April 2010; NCT01106677, 1 April 2010; NCT01106690, 1 April 2010.

Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy.[Pubmed:28352212]

Core Evid. 2017 Mar 15;12:1-10.

INTRODUCTION: Deciding on an optimal medication choice for type 2 diabetes is often challenging, due to the increasing number of treatment options. Canagliflozin is a novel glucose-lowering agent belonging to sodium-glucose co-transporter 2 (SGLT2) inhibitors. AIM: The aim of this study was to examine and summarize the evidence based on the efficacy, safety, and cost-effectiveness of Canagliflozin for type 2 diabetes. EVIDENCE REVIEW: Compared to placebo, Canagliflozin 100 and 300 mg lower glycated hemoglobin (HbA1c) by ~0.6%-0.8%, respectively. Canagliflozin appears to be slightly more effective than dipeptidyl peptidase-4 (DPP-4) inhibitors in reducing HbA1c. It also has a favorable effect on body weight and blood pressure, both versus placebo and most active comparators. However, treatment with Canagliflozin is associated with increased incidence of genital tract infections and osmotic diuresis-related adverse events. Based on short-term data, Canagliflozin is not associated with increased risk for all-cause mortality and cardiovascular outcomes. Economic evaluation studies from various countries indicate that Canagliflozin is a cost-effective option in dual- or triple-agent regimens. PLACE IN THERAPY: As monotherapy, Canagliflozin could be used in patients for whom metformin is contraindicated or not tolerated. For patients on background treatment with metformin, Canagliflozin appears to be superior to sulfonylureas with respect to body weight, blood pressure and risk for hypoglycemia, and to DPP-4 inhibitors in terms of lowering HbA1c, body weight, and blood pressure. Canagliflozin also seems to be cost-effective compared with sulfonylureas and DPP-4 inhibitors as add-on to metformin monotherapy, and compared with DPP-4 inhibitors as add-on to metformin and sulfonylurea. CONCLUSION: Current evidence on intermediate efficacy outcomes, short-term safety and cost-effectiveness support the use of Canagliflozin in patients on background treatment with metformin. Robust long-term data regarding the effect of Canagliflozin on cardiovascular endpoints will be available upon completion of the Canagliflozin Cardiovascular Assessment Study (CANVAS) trial.

The association of weight loss with patient experience and outcomes in a population of patients with type 2 diabetes mellitus prescribed canagliflozin.[Pubmed:28360528]

Diabetes Metab Syndr Obes. 2017 Mar 20;10:89-99.

OBJECTIVE: Type 2 diabetes mellitus (T2DM) is a chronic condition complicated by being overweight or obese. This study used a patient survey to assess health, satisfaction, and diabetes self-management in relation to weight management. METHODS: A survey including the Current Health Satisfaction Questionnaire, Diabetes Distress Scale, and Diabetes Treatment Satisfaction Questionnaire was administered using an online platform to a sample of 205 patients with T2DM prescribed Canagliflozin. Patients were placed into 5 groups based on their self-reported weight change since initiation of Canagliflozin: Lost >10 lbs, Lost 5-10 lbs, Lost <5 lbs, No Change, and Gained Weight. One-way ANOVAs, Kruskall-Wallis tests, and multivariable regression were used to explore differences between weight loss groups. RESULTS: The majority of patients (66.8%) reported losing weight. Compared to other groups, patients who lost >10 lbs were more likely to be engaged in a weight loss program for at least 6 months. Patients in the Lost >10 lbs and Lost 5-10 lbs groups reported the greatest satisfaction with Canagliflozin (p<0.05 for both). Multivariable analyses controlling for patient demographic and treatment characteristics revealed that losing >10 lbs was associated with reduced diabetes distress, improved A1c and blood glucose levels, and decreased perceived frequency of hyperglycemia (p<0.05). CONCLUSION: Increased positive patient outcomes, engagement in diabetes self-management, and medication satisfaction were observed among patients who reported weight loss. These findings suggest that a T2DM regimen that includes Canagliflozin as part of a weight loss regimen can help improve patient outcomes and experiences with T2DM.

Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.[Pubmed:28323512]

Curr Med Res Opin. 2017 Jun;33(6):1155-1163.

OBJECTIVE: This study evaluates the cost of achieving glycemic control with three sodium glucose co-transporter 2 (SGLT2) inhibitors, Canagliflozin, dapagliflozin, and empagliflozin, in patients with type 2 diabetes mellitus (T2DM) from the payer perspective in the United Arab Emirates (UAE). METHODS: A systematic literature review identified randomized controlled trials of antihyperglycemic agents as add-on to metformin in patients with T2DM of 26 +/- 4 weeks in duration, published by 10 September 2014. A Bayesian network-meta analysis (NMA) compared HbA1c changes with Canagliflozin 100 and 300 mg versus dapagliflozin 10 mg and empagliflozin 10 and 25 mg. The cost associated with a 1% placebo-adjusted HbA1c reduction with each SGLT2 inhibitor as add-on to metformin was calculated based on NMA results and UAE drug costs. RESULTS: In the NMA, Canagliflozin 100 and 300 mg were associated with HbA1c reductions (-0.67% and -0.79%) compared with dapagliflozin 10 mg (-0.41%) and empagliflozin 10 and 25 mg (-0.57% and -0.64%). Probabilities of Canagliflozin 100 mg performing better were 79%, 60%, and 53% versus dapagliflozin 10 mg and empagliflozin 10 and 25 mg, respectively; probabilities for Canagliflozin 300 mg performing better were 88%, 72%, and 65%, respectively. The cost per 1%-point reduction in HbA1c was projected to be lower with Canagliflozin 100 and 300 mg ($448 and $422) compared with dapagliflozin 10 mg ($785) and empagliflozin 10 and 25 mg ($527 and $563). CONCLUSIONS: Canagliflozin may provide a greater glycemic response at a lower effective cost than dapagliflozin or empagliflozin for patients with T2DM inadequately controlled with metformin from the payer perspective in the UAE.

Description

Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively.

Keywords:

Canagliflozin,842133-18-0,JNJ 24831754ZAE; JNJ 28431754; JNJ 28431754AAA; TA 7284,Natural Products,SGLT, buy Canagliflozin , Canagliflozin supplier , purchase Canagliflozin , Canagliflozin cost , Canagliflozin manufacturer , order Canagliflozin , high purity Canagliflozin

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: